Advertisement

6. Retroviruskonferenz 1999 in Chicago

Teil I
  • Ulrich Marcus
Chapter

Zusammenfassung

Mehr als 3000 HIV-Expererten aus Praxis und Forschung kamen vom 31. Januar bis 4. Februar 1999 zur 6. Retroviruskonferenz in Chicago zusammen. Die Tagung konzentriert sich in erster Linie auf Fragen der HIV-Grundlagenforschung und Therapieentwicklung, sie gilt neben der Internationalen AIDS-Konferenz als bedeutendste internationale, wissenschaftliche Konferenz zu HIV und AIDS. Die wichtigsten Ergebnisse der Konferenz wurden für Sie zusammengefaßt: Teil I des Berichtes informiert vor allem über epidemiologische und Präventionsaspekte sowie über den Stand der Impfdiskussion. Teil II (folgt in Heft 6/99) berichtet über Therapie und Immunrekonstitution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Weiss RA, Wrangham RW (1999) From Pan to pandemic. Nature 397:385–386.PubMedCrossRefGoogle Scholar
  2. 2.
    Gao F, Bailest E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH (1999) Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397: 436–441.PubMedCrossRefGoogle Scholar
  3. 3.
    Rich JD, Merriman NA, Mylonakis E, Greenough C, Flanigan TP, Mady BJ, Carpenter CJ (1999) Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Annals of Internal Medicine 130:37–39.PubMedCrossRefGoogle Scholar
  4. 4.
    Kanki PJ, Hamel DJ, Sankalé JL, Hsieh C, Thior I, Barin F, Woodcock SA, Guèye-Ndiaye A, Zhang E, Montano M, Siby T, Marlink R, Ndoye I, Essex ME, Mboup S (1999) Human immunodeficiency virus type 1 subtypes differ in disease progression. The Journal of Infectious Diseases 179:68–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Kaufmann GR, Cunningham P, Kelleher AD, Zaunders J, Carr A, Vizzard J, Law M, Cooper DA, Sydney Primary HIV Infection Study Group (1998) Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Journal of Infectious Diseases 178:1812–1815.PubMedCrossRefGoogle Scholar
  6. 6.
    Centers for Disease Control and Prevention CDC (1999) Increases in unsafe sex and rectal Gonorrhea among men who have sex with men — San Francisco, California, 1994–1997. MMWR 48:45–48.Google Scholar
  7. 7.
    Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O’Donnell K, Mofenson L, Gortmaker SL, Shapiro DE, Scott G, Jimenez E, Moore EC, Diaz C, Flynn PM, Cunningham B, Oleske J (1999) Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 281:151–157.PubMedCrossRefGoogle Scholar
  8. 8.
    Farzadegan H, Hoover, DR, Astemborski J, Lyles CM, Margolick JB, Markham RB, Quinn TC, Vlahov D (1998) Sex differences in HIV-1 viral load and progressiv to AIDS. Lancet 352:1510–1514.PubMedCrossRefGoogle Scholar
  9. 9.
    Moore RD, Cheever L, Keruly JC, Chaisson RE (1999) Lack of sex difference in CD4 to HIV-1 RNA viral load ratio. Lancet 353: 463–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Junghans J, Ledergerber B, Chan P, Weber R, Egger M, Moroni M, on behalf of ICONA Study Group (1999) Sex differences in HIV-1 viral load and progression. (Correspondence) Lancet 353:589.PubMedGoogle Scholar
  11. 11.
    Webber MP, Schoenbaum EE, Gourevitch MN, Buono D, Klein RS (1999) A prospective study of HIV disease progression in female and male drug users. AIDS 13:257–262.PubMedCrossRefGoogle Scholar
  12. 12.
    Gallant JE, Chaisson RE, Keruly JC, Moore RD (1999) Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients. AIDS 13:225–229.PubMedCrossRefGoogle Scholar
  13. 13.
    Lorenzi P, Opravil M, Hirschel B, Chave J-P, Furrer H-J, Sax H, Perneger TV, Perrin L, Kaiser L, Yerly S, Swiss HIV Cohort Study (1999) Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 13: F17–F21.PubMedCrossRefGoogle Scholar
  14. 14.
    Padberg J, Schiirman D, Grobusch M, Bergmann F (1999) Drug interaction of isotretinoin and protease inhibitors: support for the cellular retinoic acid-binding protein-1 theory of lipodystrophy? (Correspondence) AIDS 13:284–85.PubMedCrossRefGoogle Scholar
  15. 15.
    Gervasoni C, Ridolfo AL, Trifirö G, Santambrogio S, Norbiato G, Musicco M, Clerici M, Galli M, Moroni M (1999) Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 13: 465–471.PubMedCrossRefGoogle Scholar
  16. 16.
    Tebas P, Patick AK, Kane EM, Klebert MK, Simpson JH, Erice A, Powderly W, Henry K (1999) Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 13:F23–F28.PubMedCrossRefGoogle Scholar
  17. 17.
    Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, Schmidt D, Hoh R, Neese R, Macallan D, Deeks S, McCune JM (1999) Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nature Medicine 5: 83–89.PubMedCrossRefGoogle Scholar
  18. 18.
    Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, Janieson BD, Zack JA, Picker LJ, Koup RA (1998) Changes in thymic function with age and during the treatment of HIV infection. Nature 396:690–395.PubMedCrossRefGoogle Scholar
  19. 19.
    Nielsen SD, Ersboll AK, Mathiesen L, Nielsen JO, Hansen JES (1998) Highly active antiretroviral therapy normalizes the function of progenitor cells in human immunodeficiency virus-infected patients. The Journal of Infectious Diseases 178:1299–1305.PubMedCrossRefGoogle Scholar
  20. 20.
    Merrill DP, Martinez-Picado J, Tremblay C, Sax PE, Boswell SL, Wong JT, D’Aquilla RT, Walker BD, Hirsch S (1999) Improved CD4 lymphocyte outgrowth in response to effective antiretroviral therapy. The Journal of Infectious Diseases 179:345–351.PubMedCrossRefGoogle Scholar
  21. 21.
    Greenough TC, Sullivan JL, Desrosiers RC (1999) Declining CD4T-Cell counts in a person infected with nef-delected HIV-1. (Correspondence) The New England Journal of Medicine 340:237.CrossRefGoogle Scholar
  22. 22.
    van Rompay KKA, Dailey PJ, Tarara RR Canfield DR, Aguirre NL, Cherrington JM, Lamy PD, Bischofberger N, Pedersen NC, Marthas ML (1999) Early short-term 9-[2-(R)-(Phosphonomethoxy)Propyl] Adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. Journal of Virology 73:2947–2955.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283: 857–860.PubMedCrossRefGoogle Scholar
  24. 24.
    Brodie SJ, Lewinsohn DA, Patterson BK, Jiyamapa D, Krieger J, Corey L, Greenberg PD, Riddell S (1999) In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nature Med 5:34–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJD, Suresh M, Altman JD, Ahmed R (1998) Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188:2199–2204.CrossRefGoogle Scholar
  26. 26.
    Kalmas SA, Walker BD (1998) The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188:2199–2204.CrossRefGoogle Scholar
  27. 27.
    Steger KK, Waterman PM, Pauza CD(1999) Acute effects of pathogenic simian-human immunodeficiency virus challenge on vaccine-induced cellular and humoral immune responses to gag in rhesus macaques. Journal of Virology 73:1853–1859.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Johnson RP (1999) Live attenuated AIDS vaccines: hazards and drops. Nature Medicine 5:154–155.PubMedCrossRefGoogle Scholar
  29. 29.
    Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, Bronson R, Greene MF, McClure HM, Martin LN, Ruprecht RM (1999) Live attenuated, multiple deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nature Medicine 5:194–203.PubMedCrossRefGoogle Scholar
  30. 30.
    Berkhout B, Verhoef K, van Wamel JLB, Back NKT (1999) Genetic instability of live, attenuated human immunodeficiendy virus type 1 vaccine strains. Journal of Virology 73(2): 1138–1145.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Cayabyab M, Karlsson GB, Etemad-Moghadam BA, Hofmann W, Steenbeke T, Halloran M; Fanton JW, Axthelm MK, Letvin NL, Sodroski JG (1999) Changes in human immunodeficiency virus type 1 envelope glycoprote-ins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2). Journal of Virology 73(2): 976–984.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Lewis MG, Yalley-Ogunro J, Greenhouse JJ, Brennan TP, Bo Jiang J, VanCott TC, Lu Y, Eddy GA, Birx DL (1999) Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus. Journal of Virology 73(2): 1262–1270.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Joag SV, Qian Liu Z, Stephens EB, Smith MS, Kumar A, Li Z, Wang C, Sheffer D, Jia F, Foresman L, Adany I, Lifson J, McClure HM, Narayan O (1998) Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS. Journal of Virology 72(11): 9069–9078.PubMedCentralPubMedGoogle Scholar
  34. 34.
    Dittmer U, Brooks DM, Hasenkrug KJ (1999) Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nature Medicine 5:189–193.PubMedCrossRefGoogle Scholar
  35. 35.
    Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA (1999) Neutralization antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Medicine 5:204–216.PubMedCrossRefGoogle Scholar
  36. 36.
    Igarashi T, Brown C, Azadegan A, Haigwood N, Dimitrov D, Martin MA, Shibata R (1999) Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nature Medicine 5:211–216.PubMedCrossRefGoogle Scholar
  37. 37.
    Moore JP, Burton DR (1999) HIV-1 neutralizing antibodies: How full is the bottle? Nature Medicine 5:142–144.PubMedCrossRefGoogle Scholar
  38. 38.
    LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, Nunberg JH (1999) Fusioncompetent vaccines: Broad neutralization of primary isolates of HIV. Science 283: 357–362.PubMedCrossRefGoogle Scholar
  39. 39.
    Montefiori DC, Moore JP (1999) Magic of the occult? Science 283:336–337.PubMedCrossRefGoogle Scholar
  40. 40.
    Gallo RC (1998) The enigmas of Kaposi’s Sarcoma. Science 282:1837–1839.PubMedCrossRefGoogle Scholar
  41. 41.
    LaDuca JR, Love L, Abbott LZ, Dube S, Freidman-Kien AE, Poiesz BJ (1998) Detection of Human Herpesvirus 8 DNA sequences in tissues and bodily fluids. The Journal of Infectious Diseases 178:1610–1615.PubMedCrossRefGoogle Scholar
  42. 42.
    Blackbourn DJ, Osmond D, Levy JA, Lennette ET (1999) Increased Human Herpesvirus 8 seroprevalence in young homosexual men who have multiple sex contacts with different partners. The Journal of Infectious Diseases 179:237–239.PubMedCrossRefGoogle Scholar
  43. 43.
    He J, Bhat G, Kankasa C, Chintu C, Mitchell C, Duan W, Wood C (1998) Seroprevalence of Human Herpesvirus 8 among Zambian women of childbearing age without Kaposi’s Sarcoma (KS) and mother-child pairs with KS. The Journal of Infectious Diseases 178:1787–1790.PubMedCrossRefGoogle Scholar
  44. 44.
    Whitby D, Smith N A, Matthews S, O’Shea S, Sabin CA, Kulasegaram R, Boshoff C, Weiss RA, de Ruiter A, Best JM (1999) Human herpesvirus 8: seroepidemiology among women and detection in the genital tract of séropositive women. The Journal of Infectious Diseases 179:234–236.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • Ulrich Marcus
    • 1
  1. 1.Robert Koch-InstitutBerlinDeutschland

Personalised recommendations